CPT 79005 Oral Radiopharmaceutical Therapy Reimbursement

CPT code 79005 denotes oral administration of a radiopharmaceutical for therapeutic use, such as treating certain cancers. As a specific procedural code for therapeutic radiopharmaceutical delivery, it captures services where a radioactive agent is given by mouth to deliver systemic or targeted internal radiation. Nationally, use of radiopharmaceutical therapies has grown as oncology care expands and more agents receive approval, making accurate coding important for clinical documentation, billing clarity, and coverage determination.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an explanation of the code’s clinical context and service settings, typical payer considerations and coverage scope, common billing modifiers and coding interactions (listed separately), and related service lines that often appear on the claim. The publication outlines benchmarks and billing patterns where available, policy updates affecting radiopharmaceutical administration, and practical coding notes to support accurate claim submission.

This summary is intended for national audiences including billing professionals, practice managers, and policy analysts seeking a concise reference to CPT code 79005 and its role in therapeutic radiopharmaceutical services.

Billing Code Overview

CPT code 79005 describes the oral administration of a radiopharmaceutical agent for therapeutic purposes, most commonly to treat cancer or other conditions responsive to systemic radiopharmaceutical therapy. This procedure involves giving a patient a radioactive substance by mouth that delivers targeted radiation internally.

Service type: Therapeutic radiopharmaceutical administration (oral)
Typical site of service: Outpatient clinic, hospital outpatient department, or specialized infusion/radiation-therapy facility

Data not available in the input.

Clinical Context

A typical patient is an adult with metastatic thyroid carcinoma or neuroendocrine tumor scheduled to receive an oral radiopharmaceutical for targeted systemic therapy. The patient presents to an outpatient nuclear medicine or oncology infusion clinic after multidisciplinary tumor board recommendation. Pre-procedure evaluation includes verification of indication, recent labs (renal and hepatic function), pregnancy test for women of childbearing potential, medication reconciliation, and consent. The nuclear medicine physician or authorized oncology provider reviews prior imaging, documents dosing based on body weight or institutional protocol, and ensures radiation safety counseling. The radiopharmaceutical is administered orally by a licensed provider or authorized nurse under direct supervision. Post-administration monitoring occurs in a designated area for a short observation period to assess for acute adverse effects, with discharge instructions covering radiation precautions, hydration, and follow-up imaging or lab work scheduled as indicated.

Coding Specifications

Modifier	Description	When to Use
`26`	Professional component	Use when billing only the physician interpretation for associated imaging or dosimetry reports related to the therapy.
`52`

Taxonomy Code	Specialty	Notes
207RG0300X	Radiation Oncology	Radiation oncologists often prescribe and oversee radiopharmaceutical cancer therapies.
2085R0202X	Nuclear Medicine	Nuclear medicine physicians perform dosing, administration oversight, and radiation safety.
2084N0400X	Medical Oncology	Medical oncologists coordinate systemic cancer therapies and follow-up care.
363A00000X	Nurse Practitioner	Oncology NPs may obtain consent and assist with administration under provider supervision.
207L00000X	Radiation Therapist	Radiation therapists may participate in patient preparation and radiation safety processes.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C73`	Malignant neoplasm of thyroid gland	Common indication for radioiodine oral therapy used to ablate residual thyroid tissue or treat metastases.
`C77.0`	Secondary and unspecified malignant neoplasm of lymph nodes of head, face and neck	Metastatic disease that may be targeted with systemic radiopharmaceuticals in select cases.
`C78.7`	Secondary malignant neoplasm of liver and intrahepatic bile duct	Liver metastases from neuroendocrine tumors that may be treated with certain systemic radiopharmaceuticals.
`C7A.090`	Malignant carcinoid tumor of small intestine	Neuroendocrine tumors for which certain radiolabeled therapies are indicated.
`D09.0`	Carcinoma in situ of thyroid	Indication context for definitive management including radioactive therapy in selected protocols.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`79005`	Radiopharmaceutical therapy administration, oral; therapeutic, single administration	This is the primary procedure for oral radiopharmaceutical administration as described.
`78800`	Radiopharmaceutical localization of tumor or distribution of radiopharmaceutical agent, qualitative; multiple areas, single day imaging	Performed for post-therapy imaging to assess distribution of the agent when required.
`79101`	Sampling and assay of radioactivity in blood and/or urine	Used when pharmacokinetic monitoring or dosimetry requires bioassay after administration.
`77307`	Special treatment procedures, includes those requiring complex dosimetry (radiation therapy)	May be used for complex dosimetry planning associated with therapeutic radiopharmaceuticals when billed by radiation oncology.
`96413`	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug	Included as a workflow comparator for systemic therapy visits; not the same route but similar billing and monitoring considerations.

OpenPayer

Summary & Overview

CPT 79005: Oral Radiopharmaceutical Administration for Therapy